PDF herunterladen
CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2023; 83(10): 1199-1204
DOI: 10.1055/a-2160-3279
GebFra Science
Statement/Stellungnahme

Statement of the Uterus Commission of the Gynecological Oncology Working Group (AGO) on Surgical Therapy for Patients with Stage IA2–IIB1 Cervical Cancer

Artikel in mehreren Sprachen: English | deutsch
Tanja Fehm
1   Universitätsfrauenklinik der Universität Düsseldorf, CIO ABCD, Düsseldorf, Germany
,
Matthias W. Beckmann
2   Frauenklinik, Comprehensive Cancer Center ER-EMN, Universitätsklinikum Erlangen, Erlangen, Germany
,
Sven Mahner
3   Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU-Klinikum München, München, Germany
,
Dominik Denschlag
4   Frauenklinik, Hochtaunus Kliniken, Bad Homburg, Bad Homburg, Germany
,
Sara Brucker
5   Universitäts-Frauenklinik Tübingen, Department für Frauengesundheit, Universität Tübingen, Tübingen, Germany
,
Peter Hillemanns
6   Frauenklinik, Comprehensive Cancer Center Niedersachsen, Medizinische Hochschule Hannover, Hannover, Germany
,
Clemens Tempfer
7   Universitätsfrauenklinik, Comprehensive Cancer Center der Ruhr Universität Bochum (RUCCC), Bochum, Germany
,
for the Uterus Commission of the AGO and the AGO Working Group › Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

The presentation of the results of the prospective randomized international multicenter study AGO-OP.8 – CCTG CX.5 – SHAPE at the annual conference of the American Society of Clinical Oncology (ASCO) in 2023 will affect the surgical treatment of early-stage cervical cancer. In the SHAPE study, simple total hysterectomy (experimental arm) was found to be non-inferior to radical hysterectomy (standard arm) to treat patients with early-stage cervical cancer (FIGO stages [2018] IA2 – IB1 ≤ 2 cm with an infiltration depth of < 1 cm); after 3 yearsʼ follow-up the pelvic recurrence rate was 2.52% (experimental arm) compared to 2.17% (standard arm) with no statistically significant difference with regards to recurrence-free survival and overall survival rates. After weighing up the results of the SHAPE study published at the conference, the Uterus Organ Commission of AGO is of the opinion that, in addition to the use of radical hysterectomy to treat patients with invasive cervical cancer which is FIGO stage IA2 – IB1 ≤ 2 cm with an infiltration depth of < 1 cm, simple total hysterectomy may also be considered for primary surgical therapy on a case-by-case basis after suitable explanation of the associated risks. It will be necessary to wait for the data of the full publication before discussing whether this approach should be included in official guidelines and defining it as a new therapy standard.

Key words

cervical cancer - radical hysterectomy - early-stage - simple hysterectomy


Publikationsverlauf

Eingereicht: 24. August 2023

Angenommen: 24. August 2023

Artikel online veröffentlicht:
05. Oktober 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References/Literatur

  • 1 Plante M, Kwon JS, Ferguson S. et al. An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs. simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC): A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE). J Clin Oncol 2023; 41 (Suppl.) LBA5511-LBA5511
    CrossrefPubMedSuche in Google Scholar
  • 2 S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom Langversion 2.2 – März 2022 AWMF-Registernummer: 032/033O. Zugriff am 29. Juni 2023 unter: https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Zervixkarzinom/Version_2/LL_Zervixkarzinom_Langversion_2.2.pdf
    PubMed
  • 3 Uppal S, Gehrig PA, Peng K. et al. Recurrence Rates in Patients With Cervical Cancer Treated With Abdominal Versus Minimally Invasive Radical Hysterectomy: A Multi-Institutional Retrospective Review Study. J Clin Oncol 2020; 38: 1030-1040
    CrossrefPubMedSuche in Google Scholar
  • 4 Chacon E, Manzour N, Zanagnolo V. et al. SUCCOR study group. SUCCOR cone study: conization before radical hysterectomy. Int J Gynecol Cancer 2022; 32: 117-124
    CrossrefPubMedSuche in Google Scholar
  • 5 Klapdor R, Hertel H, Delebinski L. et al. Association of preoperative cone biopsy with recurrences after radical hysterectomy. Arch Gynecol Obstet 2022; 305: 215-222
    CrossrefPubMedSuche in Google Scholar
  • 6 Casarin J, Buda A, Bogani G. et al. Predictors of recurrence following laparoscopic radical hysterectomy for early-stage cervical cancer: A multi-institutional study. Gynecol Oncol 2020; 159: 164-170
    CrossrefPubMedSuche in Google Scholar
  • 7 Kim SI, Choi BR, Kim HS. et al. Cervical conization before primary radical hysterectomy has a protective effect on disease recurrence in early cervical cancer: A two-center matched cohort study according to surgical approach. Gynecol Oncol 2022; 164: 535-542
    CrossrefPubMedSuche in Google Scholar
  • 8 Schmeler KM, Frumovitz M, Ramirez PT. Conservative management of early stage cervical cancer: is there a role for less radical surgery?. Gynecol Oncol 2011; 120: 321-325
    CrossrefPubMedSuche in Google Scholar
  • 9 Schmeler KM, Pareja R, Lopez Blanco A. et al. ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer. Int J Gynecol Cancer 2021; 31: 1317-1325
    CrossrefPubMedSuche in Google Scholar
  • 10 Wu J, Logue T, Kaplan SJ. et al. Less radical surgery for early-stage cervical cancer: a systematic review. Am J Obstet Gynecol 2021; 224: 348-358
    CrossrefPubMedSuche in Google Scholar
  • 11 ECOG-ACRIN Cancer Research Group. ECOG Performance Status Scale. Zugriff am 18. August 2023 unter: https://ecog-acrin.org/resources/ecog-performance-status/
    PubMed
  • 12 Salvo G, Ramirez PT, Levenback CF. et al. Sensitivity and negative predictive value for sentinel lymph node biopsy in women with early-stage cervical cancer. Gynecol Oncol 2017; 145: 96-101
    CrossrefPubMedSuche in Google Scholar
  • 13 Ramirez PT, Frumovitz M, Pareja R. et al. Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. N Engl J Med 2018; 379: 1895-1904
    CrossrefPubMedSuche in Google Scholar